Streptomyces As a Prominent Resource of Future Anti-MRSA Drugs
REVIEW published: 24 September 2018 doi: 10.3389/fmicb.2018.02221 Streptomyces as a Prominent Resource of Future Anti-MRSA Drugs Hefa Mangzira Kemung 1,2, Loh Teng-Hern Tan 1,2,3, Tahir Mehmood Khan 1,2,4, Kok-Gan Chan 5,6*, Priyia Pusparajah 3*, Bey-Hing Goh 1,2,7* and Learn-Han Lee 1,2,3,7* 1 Novel Bacteria and Drug Discovery Research Group, Biomedicine Research Advancement Centre, School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia, 2 Biofunctional Molecule Exploratory Research Group, Biomedicine Research Advancement Centre, School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia, 3 Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia, 4 The Institute of Pharmaceutical Sciences (IPS), University of Veterinary and Animal Sciences (UVAS), Lahore, Pakistan, 5 Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia, 6 International Genome Centre, Jiangsu University, Zhenjiang, China, 7 Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences, University of Phayao, Mueang Phayao, Thailand Methicillin-resistant Staphylococcus aureus (MRSA) pose a significant health threat as Edited by: they tend to cause severe infections in vulnerable populations and are difficult to treat Miklos Fuzi, due to a limited range of effective antibiotics and also their ability to form biofilm. These Semmelweis University, Hungary organisms were once limited to hospital acquired infections but are now widely present Reviewed by: Dipesh Dhakal, in the community and even in animals. Furthermore, these organisms are constantly Sun Moon University, South Korea evolving to develop resistance to more antibiotics.
[Show full text]